FDA.reportPublic FDA data

Ondansetron

Product NDC
68071-5167
Requested package NDC
68071-5167-5
11-digit product format
680715167
Labeler code
68071
Product ID
68071-5167_49644002-1564-c254-e063-6394a90a46eb
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Ondansetron
Dosage form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Labeler
NuCare Pharmaceuticals,Inc.
Application
ANDA090469
Marketing category
ANDA
Marketing start
2010-04-12
Substance
ONDANSETRON
Active strength
8 mg/1
Pharmacologic classes
Serotonin 3 Receptor Antagonists [MoA], Serotonin-3 Receptor Antagonist [EPC]
NDC exclude flag
No
Listing certified through
2027-12-31
Current FDA listing
Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A090469-001ONDANSETRONONDANSETRON4MGTABLET, ORALLY DISINTEGRATING / ORALAB2010-04-12
A090469-002ONDANSETRONONDANSETRON8MGTABLET, ORALLY DISINTEGRATING / ORALABRS2010-04-12

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A090469-001AB
A090469-002AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-08-01 22:54:322026-06A090469-001ONDANSETRON4MGTABLET, ORALLY DISINTEGRATING / ORALAB2010-04-12a50c72e98297…
2026-08-01 22:54:322026-06A090469-002ONDANSETRON8MGTABLET, ORALLY DISINTEGRATING / ORALABRS2010-04-12a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-08-01 22:54:322026-06A090469-001AB1a50c72e98297…
2026-08-01 22:54:322026-06A090469-002AB1a50c72e98297…

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 3 · 45 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
OndansetronONDANSETRONHAWAII REPACK, INC.b76c5cc9-f1ca-428b-8989-36a66802b6502026-07-17Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONREMEDYREPACK INC.18063a64-a4c0-4bad-911b-00df5c7bb65d2026-07-07Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONBryant Ranch Prepack77397df5-5a4f-41b2-98bc-f817a1e497fc2026-07-02Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONSportpharm LLC822404ad-af08-4c62-ae38-7d9819e860792026-07-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONSt. Mary's Medical Park Pharmacy3207cf04-73b7-24ce-e054-00144ff8d46c2026-06-30Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
ONDANSETRONONDANSETRONDirect Rxb38feff2-900a-4e0c-8260-8f090edbc0bc2026-03-17Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONA-S Medication Solutions378d0963-d026-4478-8202-fbb636904a372026-02-18Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONSportpharm LLC3c4cda2f-13d9-42c5-b449-77deb06c8de52026-02-06Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONNuCare Pharmaceuticals,Inc.9dff6676-e69e-779d-e053-2995a90a7c812026-01-27Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
ndc (package): 68071-5167-5
ndc (product): 68071-5167
ndc11 (package): 68071516705
OndansetronONDANSETRONNuCare Pharmaceuticals,Inc.76666e7e-3312-6f9d-e053-2991aa0af7052026-01-23Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONNorthwind Health Company, LLCf2b502e2-03ed-fe5c-e053-2995a90a368e2026-01-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONNorthwind Health Company, LLCdb9a0d22-9339-4319-e053-2a95a90a95922026-01-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONNorthwind Health Company, LLCe07c38c0-e1c2-01de-e053-2995a90a390a2026-01-01Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONPD-Rx Pharmaceuticals, Inc.9558d296-8edd-4aa1-875a-6247f9a8374d2025-09-15Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONPD-Rx Pharmaceuticals, Inc.10afd68b-877f-4819-a314-39f2d56d5db92025-09-15Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONPreferred Pharmaceuticals, Inc.b9abd5ce-6aca-4fda-8f46-0bb5b7fdd5da2025-09-04Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONPreferred Pharmaceuticals, Inc.66ac9c17-bea7-4f8d-8a27-a1e0f9e659452025-09-03Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONPreferred Pharmaceuticals, Inc.70b48280-ef74-472b-abc3-128962bfcb052025-09-03Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONCardinal Health 107, LLCb50c1767-8a50-49ab-be31-6533021ae7c42025-08-21Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469
OndansetronONDANSETRONRising Pharma Holdings, Inc.eb74425c-c635-4d99-8e98-e63e7359fb892025-07-17Warnings, Adverse reactionsExact identifier
application applno (ANDA): 090469
application number: ANDA090469

Additional Listing Data#

Finished product
Yes
Brand name base
Ondansetron
Listing expiration
2027-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
ONDANSETRON8 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
4AF302ESOSInternal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
312087Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
IdentifierFDA.report destination
9dff6676-e69e-779d-e053-2995a90a7c81Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d9bd4853-037c-6968-f4d4-9bb9a0efd1eaProduct name220250722
32e23bc9-ce14-4555-bb6d-bcb654d7d296Product name120201015
e459f50a-1553-4aab-b6bd-1e5f0c211c49Product name120201015
909480fe-0d18-c1c1-a658-0bd9a7131822Product name520170829

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
68071-5167-42024-06-20C16284748780-1f386c649-d12c-0266-e053-dadaa90a7c1aThese highlights do not include all the information needed to use ONDANSETRON ORALLY DISINTEGRATING TABLETS, safely and effectively. See full prescribing information for ONDANSETRON ORALLY DISINTEGRATING TABLETS. ONDANSETRON orally disintegrating tablets Initial U.S. Approval: 1991
68071-5167-42023-01-30C16284748780-1f386c649-d12c-0266-e053-dadaa90a7c1aThese highlights do not include all the information needed to use ONDANSETRON ORALLY DISINTEGRATING TABLETS, safely and effectively. See full prescribing information for ONDANSETRON ORALLY DISINTEGRATING TABLETS. ONDANSETRON orally disintegrating tablets Initial U.S. Approval: 1991

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68071-5167-4Ondansetron4 in 1 BOXTABLET, ORALLY DISINTEGRATING44
68071-5167-5Ondansetron15 in 1 BOXTABLET, ORALLY DISINTEGRATING154

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68071-5167ONDANSETRON TABLET, ORALLY DISINTEGRATING [NUCARE PHARMACEUTICALS,INC.]3Current NDC, Legacy NDC, 2 package rows20240621_9dff6676-e69e-779d-e053-2995a90a7c81.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
312087ondansetron 8 MG Disintegrating Oral TabletPSN9dff6676-e69e-779d-e053-2995a90a7c814
312087ondansetron 8 MG Disintegrating Oral TabletSCD9dff6676-e69e-779d-e053-2995a90a7c814

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startSampleExclude flagStatus
68071-5167-56807151670515 TABLET, ORALLY DISINTEGRATING in 1 BOX (68071-5167-5) 2026-01-27NoNoCurrent